Haris Babačić

460 total citations
16 papers, 266 citations indexed

About

Haris Babačić is a scholar working on Molecular Biology, Infectious Diseases and Cellular and Molecular Neuroscience. According to data from OpenAlex, Haris Babačić has authored 16 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Infectious Diseases and 3 papers in Cellular and Molecular Neuroscience. Recurrent topics in Haris Babačić's work include Genetic Neurodegenerative Diseases (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Glycogen Storage Diseases and Myoclonus (2 papers). Haris Babačić is often cited by papers focused on Genetic Neurodegenerative Diseases (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Glycogen Storage Diseases and Myoclonus (2 papers). Haris Babačić collaborates with scholars based in Sweden, Germany and United Kingdom. Haris Babačić's co-authors include Benedikt Schoser, Maria Pernemalm, Janne Lehtiö, Hanna Eriksson, Christian P. Kamm, Jürg Kesselring, Anke Salmen, Claudio Gobbi, Pasquale Calabrese and Caroline Pot and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Haris Babačić

12 papers receiving 261 citations

Peers

Countries citing papers authored by Haris Babačić

Since Specialization

Citations

This map shows the geographic impact of Haris Babačić's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haris Babačić with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haris Babačić more than expected).

Fields of papers citing papers by Haris Babačić

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haris Babačić. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haris Babačić. The network helps show where Haris Babačić may publish in the future.

Co-authorship network of co-authors of Haris Babačić

This figure shows the co-authorship network connecting the top 25 collaborators of Haris Babačić. A scholar is included among the top collaborators of Haris Babačić based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haris Babačić. Haris Babačić is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Comparative evaluation of Olink Explore 3072 and mass spectrometry with peptide fractionation for plasma proteomics 2025 ·Communications Chemistry ·(unknown), Haris Babačić, (unknown), Xiaofang Cao, Jenny Forshed, Lars E. Eriksson, Janne Lehtiö, Claudia Fredolini, Mikael Åberg, Maria Pernemalm	0
2	In-depth patient-specific analysis of tumor heterogeneity in melanoma brain metastasis: Insights from spatial transcriptomics and multi-region bulk sequencing 2025 ·Translational Oncology ·Nidhi Sharma, (unknown), Georgios Mermelekas, Kim Thrane, Joakim Lundeberg, Alia Shamikh, (unknown), Haris Babačić, (unknown), Janne Lehtiö, Maria Pernemalm, Hanna Eriksson	0
3	Improving outcome measures in late onset Pompe disease: Modified Rasch‐Built Pompe‐Specific Activity scale 2024 ·European Journal of Neurology ·(unknown), Mike Horton, Stephan Wenninger, Haris Babačić, Benedikt Schoser, (unknown), (unknown), Pascal Laforêt, Sonia Segovia, Jordi Díaz‐Manera, Kristl G. Claeys, Tiziana Mongini, Olimpia Musumeci, (unknown), Thomas Hundsberger, Esther Brusse, Pieter A. van Doorn, Ans T. van der Ploeg, Nadine A. M. E. van der Beek	1
4	Comprehensive proteomics and meta-analysis of COVID-19 host response 2023 ·Nature Communications ·Haris Babačić, Wanda Christ, J.E. Araújo, Georgios Mermelekas, Nidhi Sharma, Janne Tynell, Marina García, Renata Varnaitė, Hilmir Ásgeirsson, Hedvig Glans, Janne Lehtiö, Sara Gredmark‐Russ, Jonas Klingström, Maria Pernemalm	16
5	Glioblastoma stem cells express non‐canonical proteins and exclusive mesenchymal‐like or non‐mesenchymal‐like protein signatures 2022 ·Molecular Oncology ·Haris Babačić, Silvia Galardi, Husen M. Umer, Mats Hellström, Lene Uhrbom, (unknown), (unknown), Serena Pellegatta, Alessandro Michienzi, Gianluca Trevisi, Annunziato Mangiola, Janne Lehtiö, Silvia Anna Ciafrè, Maria Pernemalm	3
6	ANTI-SARS-COV-2 ANTIBODIES IN MACEDONIAN HEALTHCARE WORKERS: AN INTERIM ANALYSIS 2021 ·Katerina Tosheska Trajkovska, Haris Babačić, (unknown), (unknown), Jasna Bogdanska, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
7	Plasma proteome alterations by MAPK inhibitors in BRAF-mutated metastatic cutaneous melanoma 2021 ·Neoplasia ·Haris Babačić, Hanna Eriksson, Maria Pernemalm	0
8	In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma 2020 ·Journal for ImmunoTherapy of Cancer ·Haris Babačić, Janne Lehtiö, Yago Pico de Coaña, Maria Pernemalm, Hanna Eriksson	47
9	Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study 2019 ·Journal of Neurology ·Federica Montagnese, Haris Babačić, Peter Eichhorn, Benedikt Schoser	18
10	CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review 2019 ·PLoS ONE ·Haris Babačić, Aditi Mehta, Olivia M. Merkel, Benedikt Schoser	25
11	Plasma proteomic analyses and treatment predictive biomarker candidates in melanoma patients receiving immune checkpoint blockade or targeted therapy. 2019 ·Journal of Clinical Oncology ·Hanna Eriksson, Haris Babačić, Janne Lehtiö, Maria Pernemalm	1
12	The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most? 2018 ·Multiple Sclerosis and Related Disorders ·(unknown), Anke Salmen, Giulio Disanto, Haris Babačić, Pasquale Calabrese, Andrew Chan, Christian P. Kamm, Jürg Kesselring, Jens Kühle, Claudio Gobbi, Caroline Pot, Milo A. Puhan, Viktor von Wyl	112
13	How to Interpret Abnormal Findings of Spirometry and Manometry in Myotonic Dystrophies? 2018 ·Journal of Neuromuscular Diseases ·Haris Babačić, (unknown), Kristina Ståhl, Federica Montagnese, Vindi Jurinović, Benedikt Schoser, Stephan Wenninger	3
14	Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study 2018 ·Journal of Neurology ·Stephan Wenninger, (unknown), Haris Babačić, Kristina Ståhl, Benedikt Schoser	20
15	Falls and resulting fractures in Myotonic Dystrophy: Results from a multinational retrospective survey 2017 ·Neuromuscular Disorders ·Cecilia Jimenez‐Moreno, Joost Raaphorst, Haris Babačić, Libby Wood, Baziel G.M. van Engelen, Hanns Lochmüller, Benedikt Schoser, Stephan Wenninger	18
16	Association of Killer Cell Immunoglobulin-Like Receptor Genes with Pandemic Influenza A (H1N1)pdm09 Infection in Critically Ill Macedonian Patients 2012 ·Macedonian Journal of Medical Sciences ·Александар Петличковски, (unknown), (unknown), (unknown), Haris Babačić, (unknown), (unknown), Katerina Spasovska, Мирко Спироски, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact